Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27653000
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Opin+Endocrinol+Diabetes+Obes
2016 ; 23
(6
): 440-444
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
An update on vitamin D for clinicians
#MMPMID27653000
Hansen KE
; Johnson MG
Curr Opin Endocrinol Diabetes Obes
2016[Dec]; 23
(6
): 440-444
PMID27653000
show ga
PURPOSE OF REVIEW: The clinical benefits of vitamin D therapy have received
substantial attention over the past decade. Recently, several trials looked to
clarify the optimal vitamin D dose or serum level needed to promote human health.
The purpose of this review is to highlight selected studies published since
January 2015. RECENT FINDINGS: Several recent trials challenge whether serum
vitamin D levels at least 30?ng/ml promote human health. In postmenopausal women
with 25-hydroxyvitamin D [25(OH)D] levels 21?±?3?ng/ml, high-dose vitamin D for 1
year increased calcium absorption by 1%, without changes in bone mineral density,
physical function, or falls when compared with low-dose vitamin D and placebo.
High-dose vitamin D increased risk of falling in 200 adults 78?±?5 years old with
baseline 25(OH)D levels of ?19?±?9?ng/ml. High-dose vitamin D in adults increased
the number and duration of upper respiratory tract infections compared with
placebo. Asthma patients achieving 25(OH)D levels more than 30?ng/ml during a
trial experienced more respiratory infections than those not achieving such
levels. SUMMARY: Recent studies are congruent with the Institute of Medicine's
conclusion that humans are vitamin D replete when their serum 25(OH)D levels are
at least 20?ng/ml. Higher levels seem to promote falls and respiratory
infections.
|Accidental Falls/statistics & numerical data
[MESH]
|Aged
[MESH]
|Aged, 80 and over
[MESH]
|Asthma
[MESH]
|Bone Density
[MESH]
|Calcium, Dietary/pharmacokinetics/therapeutic use
[MESH]
free
free
free
